Chui Y. Mah
Adelaide, SA, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer.
Journal: British journal of cancer
Published: December 12, 2022
Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer.
Journal: British journal of cancer
Published: December 08, 2022
Endocrine Disruptor Compounds-A Cause of Impaired Immune Tolerance Driving Inflammatory Disorders of Pregnancy?
Journal: Frontiers in endocrinology
Published: September 17, 2020
ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
Journal: Cancer research
Published: July 23, 2020
Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
Journal: Molecular cancer research : MCR
Published: June 26, 2020
LC3-Associated Phagocytosis (LAP): A Potentially Influential Mediator of Efferocytosis-Related Tumor Progression and Aggressiveness.
Journal: Frontiers in oncology
Published: April 18, 2020
Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis.
Journal: eLife
Published: December 04, 2019
Lipogenic effects of androgen signaling in normal and malignant prostate.
Journal: Asian journal of urology
Published: May 08, 2019
Peri-prostatic adipose tissue: the metabolic microenvironment of prostate cancer.
Journal: BJU international
Published: February 21, 2018
Showing 1-12 of 12
Last Updated: 09/26/2026